We are live on ! Find out more

Solventum

SOLV

Market cap $14.2B

83.56 USD

+1.71

2.09%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

83.56

0.00

0%

1 day

2.09%

5 days

-3.87%

1 month

-6.45%

3 months

-5.64%

6 months

25.67%

Year to date

5.75%

1 year

19.75%

5 years

4.45%

10 years

4.45%

About: In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Employees: 20,000

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 67.7%

Neutral 29%

Negative 3.2%

Zacks Investment Research

Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks Investment Research

Here's Why Solventum (SOLV) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Solventum (SOLV) is a Strong Value Stock

Zacks Investment Research

SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy

Solventum gains FDA clearance to combine Restrata Matrix with V.A.C. Therapy, potentially expanding wound care applications and supporting long-term growth.

SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes Clearance pairs innovative synthetic electrospun fiber matrix technology with an industry-leading negative pressure wound therapy to optimize healing EAGAN, Minn., Oct. 19, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

Zacks Investment Research

Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?

Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?

Zacks Investment Research

Why Solventum (SOLV) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Solventum (SOLV) is a Top Value Stock for the Long-Term

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Stock Picks From Seeking Alpha's September 2026 New Analysts

Zacks Investment Research

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation.

Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

See News Rankings

Price charts implemented using Lightweight Charts™